<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="239">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465632</url>
  </required_header>
  <id_info>
    <org_study_id>GLK-1403</org_study_id>
    <nct_id>NCT02465632</nct_id>
  </id_info>
  <brief_title>To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) to the Marketed Product BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% (Valeant Pharmaceuticals, US) in the Treatment of Acne Vulgaris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals Ltd. India</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Pharmaceuticals Ltd. India</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study,
      designed to compare the efficacy and safety of generic Clindamycin 1%/ Benzoyl peroxide 5%
      topical gel (Glenmark Generics, Ltd), and the marketed product BenzaClin® Topical Gel,
      Clindamycin 1%/ Benzoyl peroxide 5% (Valeant Pharmaceuticals, US) in the treatment of acne
      vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean percent reduction from baseline to Week 10 in the number of inflamed lesions (papules/pustules)</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean percent reduction from baseline to Week 10 in the number of non-inflamed lesions (open and closed comedones)</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects considered to be a &quot;Clinical Success&quot; using the dichotomized IGA</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apply a thin layer of gel to the face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>apply a thin layer of the gel to the face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo topical gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>apply a thin layer of the gel to the face</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel</intervention_name>
    <arm_group_label>Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%</intervention_name>
    <arm_group_label>BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo topical gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant, non-lactating female, ≥12 and ≤40 years of age with a clinical
             diagnosis of acne vulgaris.

          2. Have facial acne with: ≥20 facial inflammatory lesions (papules and pustules) and ≥25
             non-inflammatory lesions (open and closed comedones), and ≤2 nodulocystic lesions
             (nodules and cysts) and have an IGA score of 2, 3 or 4.

        Exclusion Criteria:

          1. Subject has more than 2 facial nodular lesions; any nodules present will be
             documented but not included in the inflammatory lesion count for analysis.

          2. Subject has active cystic acne.

          3. Subject has acne conglobata.

          4. Subjects with excessive facial hair such as beards, sideburns, moustaches, etc. that
             would interfere with the diagnosis or assessment of acne.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahesh V Deshpande</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharmaceuticals Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph M Krahe</last_name>
    <phone>412-363-3300</phone>
    <phone_ext>545</phone_ext>
    <email>JMKrahe@novumprs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Glenmark Investigational Site 13</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 6</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 15</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site12</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 10</name>
      <address>
        <city>Belize City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 11</name>
      <address>
        <city>Belize City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 4</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 1</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 8</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 9</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 2</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 5</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site7</name>
      <address>
        <city>Upper St. Clair</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 14</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 3</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 25, 2015</lastchanged_date>
  <firstreceived_date>June 4, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
